Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations - Concepedia

Concepedia

Publication | Open Access

Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations

DOI Full Paper Access

132

Citations

14

References

2015

Year

Joanna Sieczkowska, Dorota Jarzębicka, Aleksandra Banaszkiewicz, Anna Plocek, Agnieszka Gawrońska, Ewa Toporowska‐Kowalska, Grzegorz Oracz, Monika Meglicka, Jarosław Kierkuś

Journal of Crohn s and Colitis

Abstract

Switching from infliximab originator to its biosimilar seems to be a safe option in children with CD. After the switch the biosimilar was just as effective as the originator.

References

	Year	Citations

Page 1